anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Among individuals with recent syncope, recurrence of syncope while driving might incapacitate a driver and cause a motor vehicle crash. Current driving restrictions assume that some forms of syncope transiently increase crash risk. We evaluated whether syncope is associated with a transient increase in crash risk.
METHODS: We performed a case-crossover analysis of linked administrative health and driving data from British Columbia, Canada (2010 to 2015). We included licensed drivers who visited an emergency department with "syncope and collapse" and who were involved as a driver in an eligible motor vehicle crash, both within the study interval. Using conditional logistic regression, we compared the rate of emergency visits for syncope in the 28 days before crash (the "pre-crash interval") with the rate of emergency visits for syncope in 3 self-matched 28-day control intervals (ending 6, 12, and 18 months before the crash).
RESULTS: Among eligible crash-involved drivers, 47 of 3026 pre-crash intervals and 112 of 9078 control intervals had emergency visits for syncope, indicating syncope was not significantly associated with subsequent crash (1.6% vs 1.2%; adjusted odds ratio [OR], 1.27; 95% confidence interval [CI], 0.90-1.79; P = 0.18). There was no significant association between syncope and crash in subgroups at higher risk for adverse outcomes after syncope (eg, age > 65 years, cardiovascular disease, cardiac syncope).
CONCLUSIONS: In the context of prevailing modifications of driving behaviour after syncope, an emergency department visit for syncope did not transiently increase the risk of subsequent traffic collision. Overall crash risks after syncope appear to be adequately addressed by current driving restrictions.
BACKGROUND: Recurrent and complex stone disease may be considered a challenging disease. In 2018, the Calculus group of the SIU (Italian Society of Urology) set itself the goal of establishing the minimum requirements for a center that could continuously manage urolithiasis pathology, named a Stone Center. In this study we present the results of a pilot survey carried out in 2019 with the aim of drawing a map of the situation of Italian urological centers dealing with urinary stones.
METHODS: A total of 260 national urology departments dealing with urolithiasis surgery were contacted for this study. A survey was issued to each of the centers to determine the number of patients treated for urinary stones and the amount of procedures performed per year: 1) extracorporeal shock wave lithotripsy ESWL; 2) ureterorenoscopy URS; 3) retrograde intrarenal surgery RIRS; 4) percutaneous nephrolithotomy PCNL.
RESULTS: Out of 260 centers contacted, 188 fulfilled the survey. Outcomes were quite variable, with approximately 37% of the centers lacking a lithotripter, and 46% of those that did have it performing fewer than 100 treatments per year. In terms of endoscopic procedures, more than 80% of the centers contacted performed URS or RIRS; however, when it came to percutaneous lithotripsy, these numbers dropped significantly; 33% of the centers contacted did not perform PCNL, and of those who did, 18% had less than 5 years of experience as a center.
CONCLUSIONS: Our survey shows a very heterogeneous national picture about urolithiasis treatments. Our goal is to create national paradigms to be able to define stone centers where the patient suffering from complex urinary stones can find a network of professionals with an adequate armamentarium suitable for the management of their pathology.
Postoperative CA19-9 elevation after pancreatic cancer resection suggests recurrence but can also occur in benign conditions. This study aimed to investigate the interpretation of postoperative CA19-9 elevation after pancreatic cancer surgery in terms of cancer recurrence. A cohort of patients undergoing pancreatectomy for pancreatic cancer at our hospital was included. Among them, 52 patients exhibited postoperative CA19-9 elevation without radiological evidence of recurrence. These patients were evaluated with follow-up CA19-9 measurements. The CA19-9 increase rates were calculated based on the first elevation and the follow-up measurement. The association between the CA19-9 increase rate and tumor recurrence was assessed. Patients with a CA19-9 increase rate of ≥ 30% had a significantly higher frequency of recurrence within 3 months compared to those without such an increase (p = 0.0002). Multivariate analysis demonstrated that a CA19-9 increase rate of ≥ 30% was an independent risk factor for recurrence (odds ratio 8.17, p = 0.0309). The CA19-9 value at the first elevation (p = 0.1794) and at the follow-up measurement (p = 0.1121) were not associated with recurrence. After the first postoperative CA19-9 elevation, the CA19-9 increase rate based on follow-up measurements can serve as a predictive factor for tumor recurrence.
The invention provides middle-temperature enema coffee. The processing of the enema coffee emphasizes maintenance of effective constituents. Due to the adoption of low-temperature roasting, the important constituents demanded by the coffee enema can be better maintained, but when the temperature is lower, the required processing time is longer, so that the production efficiency is greatly reduced, and the product cost is correspondingly and greatly increased; when the temperature is higher, the required processing time is shorter, so that the production efficiency is greatly improved, and the product cost is correspondingly and greatly increased. Therefore, the problem about how to find a balance point for controlling the production cost and maintaining the important constituents demanded by coffee enema from the technology appears. Middle-temperature roasting is a simple and direct scheme. The invention belongs to the field of coffee roasting (baking) production technology and particularly relates to a method suitable for the middle-temperature roasting (baking) of the enema coffee. According to the invention, during roasting, temperature is controlled to be relatively low, time cooperation is performed, and the degradation of the heating temperature is utilized, so that more components, which are beneficial for detoxification and maintenance of bodies, are generated from the coffee, and meanwhile, the original beneficial components are degraded less. Therefore, the dedicated enema coffee, which is provided with relative higher contents of palmitate and other beneficial components and is suitable for enema, is produced.
The invention relates to a herbal thermal patch and a production method thereof. A spontaneous-heating agent in the thermal patch comprises 40-60% of iron powder, 10-30% of active carbon, 3-5% of salt, 5-15% of herbal medicine and 15-20% of water. The herbal medicine comprises 3-5 parts of lavender, 3-5 parts of mentha haplocalyx, 1-3 parts of barbados aloe, 1-3 parts of motherwort and 1-3 parts of sandalwood. The production method includes crushing the herbal medicine, mixing the crushed herbs with the iron powder, the active carbon and the salt, adding water into the mixture and stirring the mixture uniform to prepare particles, and drying the particles and packing the same with package bags. A heater is combined with the herbal medicine organically, so that the herbal thermal patch can warm a user in winter, has functions of refreshing and medical hot compress, and also has obvious healthcare and therapy effects to diseases such as gall and inhibited bending and stretching, stomach cold, stomachache and the like caused by rheumatism, rheumatoid arthritis, joint sprains, joint surrounding soft tissue strain and the like. In addition, the herbal thermal patch is convenient to carry, good in heating effect, free of side effect, free of polluting clothes, and high in practicability.
Aswithallalpha-blockers,prazosinhydrochloridemaycause syncopewithsuddenlossofconsciousness.Inmost cases,thisisbelievedtobe duetoanexcessivepostural hypotensiveeffect,althoughoccasionallythesyncopal episodehasbeen precededby aboutofseveretachycardia withheartratesof120–160beatsperminute.Syncopalepisodeshaveusuallyoccurredwithin30to90minutesoftheinitialdoseofthedrug;occasionally,they havebeenreportedinassociationwith rapiddosageincreasesorthe introductionofanotherantihypertensive drugintotheregimenofa patient takinghighdosesofprazosinhydrochloride.Theincidenceof syncopal episodesisapproximately 1%inpatientsgivenaninitialdoseof2mgorgreater.Clinicaltrialsconductedduring theinvestigationalphaseofthisdrugsuggestthatsyncopal episodescanbeminimizedbylimitingtheinitialdoseofthe drugto1mg,bysubsequentlyincreasingthedosages lowly, and by introducing any additional antihypertensivedrugsintothe patient'sregimenwithcaution(seeDOSAGE AND ADMINISTRATION).

Hypotension may develop in patients given prazosin hydrochloride who are also receiving a beta- blocker such as propranolol.

If syncope occurs, the patient should be placed in the recumbent position and treated supportively as necessary. This adverse effect is self-limiting and in most cases does not recur after the initial period of therapy or during subsequent dose titration.

Patients should always be started on the 1 mg capsules of prazosin hydrochloride. The 2 mg and 5 mg capsules are not indicated for initial therapy.

More common than loss of consciousness are the symptoms often associated with lowering of the blood pressure, namely, dizziness and lightheadedness. The patient should be cautioned about these possible adverse effects and advised what measures to take should they develop. The patient should also be cautioned to avoid situations where injury could result should syncope occur during the initiation of prazosin hydrochloride therapy.

Priapism

Prolonged erections and priapism have been reported with alpha-1 blockers including prazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.
In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
Safety and effectiveness of ZOMIG Tablets in pediatric patients have not been established. Therefore, ZOMIG is not recommended for use in patients under 18 years of age. 

One randomized, placebo-controlled clinical trial evaluating zolmitriptan tablets (2.5, 5 and 10 mg) in pediatric patients aged 12-17 years evaluated a total of 696 adolescent migraineurs. This study did not establish the efficacy of zolmitriptan compared to placebo in the treatment of migraine in adolescents. Adverse events observed were similar in nature and frequency to those reported in clinical trials in adults. 

Postmarketing experience with ZOMIG and other triptans includes a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults.
Embodiments of the present technology include methods for detecting blood samples for sepsis. The method can comprise the following steps: a blood sample is received from an individual. The method may further comprise: instructions for analyzing the blood sample for sepsis are executed. Additionally, the method may include: values of a set of features in a blood sample are measured. The set of features is determined prior to measuring the values. The method may further comprise: the values of the feature set are analyzed to produce a representation of the suspicion of sepsis. Additionally, the method may include: the representation is displayed. Embodiments also include a system for detecting a blood sample for sepsis.
A skin preparation for external use which contains antibacterial zeolite and an ethyelenediaminehydroxyethyltriacetic acid trisalt. A skin preparation for external use which contains antibacterial zeolite and alum and/or baked alum. A skin preparation for external use which contains antibacterial zeolite and polyoxyethylene polyoxypropylene 2- decyltetradecyl ether. It is intended to provide a skin preparation for external use containing antibacterial zeolite which has an effect of preventing the skin preparation for external use from color change or relieving the extent of the color change. It is also intended to provide a skin preparation for external use which is excellent in the preparation stability and the texture in using. It is furthermore intended to provide a skin preparation for external use which has an effect of preventing clothes from staining due to the adhesion of the skin preparation for external use or relieving the extent of the staining.
A visualization device for diagnosis and therapy monitoring of a treatment of biological tissue is disclosed. The visualization device comprises a camera and an image processor. The latter is configured to detect reference structures present on the tissue in images created by the camera. The image processor detects and tracks optical indicators created by the examination, e.g. in a staining test. The optical indicators can be stained areas. Due to the detection and tracking of the structures, the image processing device determines changes in perspective and creates transformation rules. By means of the latter, the image processing device inserts the indicators, representations and treatment points at the correct position into the reference image irrespective of position changes of the camera, the patient and tissue distortions. The optical indicators characterizing tissue in need of treatment are detected in the correct position independent of patient movements and movements of the treating person.
Each patient was allowed to warm up for 10 minutes on the bicycle ergometer before each retrograde walking session. The patients were instructed to walk backwards for 10 min on a flat surface for a distance of 30 m at a comfortable speed supervised by the physiotherapist. Patients were required to walk backwards without looking behind. Safety measures were taken to ensure patients' well-being during retro walking. The physiotherapist stood beside the patients, gave them moral support, and guided them through the walking path till the patients are confident to walk on their own. The patient is also encouraged to increase their speed throughout the 4 weeks of rehabilitation.
Geriatric patients (those 65 years of age and older), compared to younger adult patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.7)]. In addition, the risk of diclofenac-associated adverse reactions may be greater in geriatric patients with renal impairment or those taking concomitant ACE inhibitors or ARBs [see Drug Interactions (7)and Use in Specific Populations (8.6)]. 

Avoid use of diclofenac sodium and misoprostol in geriatric patients with cardiovascular and/or renal risk factors. If use cannot be avoided, use the lowest recommended dosage for the shortest duration and monitor for cardiac and renal adverse reactions [see Dosage and Administration (2.1)]. Monitor renal function in geriatric patients during treatment with diclofenac sodium and misoprostol, especially in patients with concomitant use of ACE inhibitors or ARBs.

Of the 2,184 patients in clinical studies with diclofenac sodium and misoprostol, 557 (25.5%) were 65 years of age and over. No overall differences in effectiveness were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in effectiveness between geriatric patients and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.

No clinically meaningful differences in the pharmacokinetics of diclofenac and misoprostol were observed in geriatric patients compared to younger adult patients [see Clinical Pharmacology (12.3)].
The study will consist of 4 periods: Screening (up to 28 days), Lead-in period (Day -28), Treatment (up to 24 cycles or 1 year, whichever occurs first), and Follow-up (up to 1 year). There will be a lead-in period on Day -28 for each dose escalation cohort in which the single-dose pharmacokinetics of ZKAB001 will be characterized prior to initiation of continuous dosing in the first cycle of treatment. The lead-in period duration, PK time-points, doses and/or regimens used in subsequent cohorts may be modified based on the exposure (AUC) observed during the lead-in period (although the number of PK samples will not be increased). Treatment of continuous dosing is up to 24 cycles or 1 year, until as per investigator's opinion, subjects experience disease progression (evaluated by RECIST 1.1 and immune-related response criteria irRECIST), no clinical benefit, or intolerable toxicity. If investigators suspect subjects experience pseudoprogression or has evidence to prove "mixed response", subjects can continue to accept treatment as investigator decided.

The study was divided into two stages. After the recommended phase II dose (RP2D) is determined in the first stage, the sample size will be amplified with RP2D in the second stage. When a total of 15 cases are included in the two stages, an interim analysis will be conducted to decide whether to expand the total number of cases to 60 based on the results of the analysis. If more than 2 cases of response will be observed in 15 cervical cancer subjects, 45 cases (with a total sample size of 60 cases) could be included to further observe the safety and efficacy.
The present invention relates to a technology for preparing a Chinese medicine preparation by a multienzyme ultrasonic emulsification method. The present invention is characterized in that a water decocted agent or an extracting agent of the traditional Chinese medicine is added with pepsin, papain and cellulase for ultrasonic emulsification for 30 to 40 minutes under ordinary pressure at 28 DEG C to 36 DEG C and 5.6 to 6.3 of pH value. Then, the temperature is regulated to 90 DEG C to 100 DEG C, and the time is continuous for 30 minutes. The mixed materials are left to stand and naturally cooled for 6 hours, and the pH value is regulated to 7.1 to 7.5 at a temperature of 28 DEG C to 36 DEG C. Pancreatin is added under ordinary pressure for ultrasonic emulsification for 30 to 40 minutes, the temperature is regulated to 90 DEG C to 100 DEG C, and the time is continuous for 40 to 50 minutes. Then, the mixed materials are naturally cooled and left to stand for 24 hours, the pH value is regulated to 7.1 to 7.3, and the relative density is from 1.10 to 1.15. The physic liquor is siphoned, and preparation for entering injections, pills, medicinal powder, etc. is carried out. Multienzyme is added for preparing the Chinese medicine by the present invention, so the medicine agent contains plentiful biologically active substances which can be absorbed, wherein small molecules of polypeptide, polysaccharide, etc. for enhancing immunological functions can be enhanced by 27.3% to 18.5%, and the tannin content is reduced by 31.4%.
INTRODUCTION: The primary aim was to evaluate changes in health-related quality of life (HRQoL) in a real-life population among younger (< 70 years) and older patients with metastatic colorectal cancer (mCRC) during the first year of palliative chemotherapy. The secondary aims were to assess the impact of chemo-break on HRQoL and to report overall survival (OS).
MATERIALS AND METHODS: Patients with newly diagnosed mCRC, ≥ 18 years, and scheduled for first line palliative chemotherapy were included in this multicentre longitudinal observational study. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (0-100) was filled in at baseline and every second month. Changes or differences in QoL scores of >20, 10-20, and 5-10 points were considered to be of large, moderate, and small clinical magnitude, respectively. Comparing means of different QoL scores between groups or over time, a threshold of 5-10 was considered the minimally important difference (MID). Treatments, patient characteristics, and tumour characteristics were prospectively registered.
RESULTS: A total of 214 patients were included, and 146 were alive after one year. Four months after start of treatment, large deteriorations in fatigue and physical functioning were reported by 40% and 25% of the patients, respectively. Changes in global QoL, physical functioning, role functioning, fatigue, pain, and nausea/vomiting were not significantly different between the age groups and reached baseline levels after one year. Patients on chemo-break reported significant improvements in several HRQoL domains. Median OS was 17.5 months [95% confidence interval 14.4-20.5] with no difference between younger and older patients.
DISCUSSION: Older patients did not experience more deterioration in HRQoL than younger patients during the first year of palliative chemotherapy. Measures to mitigate the deteriorations in fatigue and physical functioning observed during the first months of palliative treatment are warranted.
TRIAL REGISTRATION: NCT02395224, March 23, 2015, retrospectively registered.
The invention relates to a tumour-associated peptide containing an amino acid sequence, which is selected from the group consisting of SEQ ID No. 1 to SEQ  ID No. 79 of the enclosed sequence protocol. Said peptide has the capacity to bond to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of the peptides for producing a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
Intraperitoneal Cystic Lymphangioma (CL) is a rare benign malformative disease of lymphatic origin, with a wide range of clinical symptoms. Diagnosis is based on imaging tests and confirmed by histology. We here report the case of a 54-year-old woman presenting with chronic abdominal pain, with no effect on general condition. Radiological assessment showed a benign mesenteric cystic formation consistent with a cystic lymphangioma. Complete surgical excision of the cystic mass after puncture-aspiration was performed via midline laparotomy, with an uncomplicated postoperative course. Histological examination of the lumpectomy confirmed the diagnosis of LK of the mesocolon. At 12 months, the patient was asymptomatic and no recurrence was observed.